Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DMAA Product OxyElite Pro Named Potential Link In Acute Hepatitis Cases

This article was originally published in The Tan Sheet

Executive Summary

FDA is investigating 29 reports of acute non-viral hepatitis in Hawaii, and the state Department of Health says 24 cases share a common link to the use of products labeled as USPlabs’ DMAA product, OxyElite Pro.

You may also be interested in...



GNC Supply Chain Reform Pays Dividends In DoJ Settlement From DMAA Investigation

DoJ announces a "non-prosecution agreement" that requires GNC to pay $2.25m and to cooperate in dietary supplement market investigations conducted by FDA and other federal agencies, including the current litigation against USPlabs.

Federal Sweep Nets 40 Criminal, Civil Cases For Spiked Supplements, Disease Claims

A deputy assistant attorney general clarifies that ongoing investigations target “unlawful makers and marketers of dietary supplements,” but DoJ and other agencies broadly warn the entire industry about the potential for additional criminal cases as well as civil complaints.

Federal Sweep Nets 40 Criminal, Civil Cases For Spiked Supplements, Disease Claims

A deputy assistant attorney general clarifies that ongoing investigations target “unlawful makers and marketers of dietary supplements,” but DoJ and other agencies broadly warn the entire industry about the potential for additional criminal cases as well as civil complaints.

Related Content

Topics

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel